| Dr Joseph A Shehadi, MD | |
|
807 Farson St Ste 136, Belpre, OH 45714-1068 | |
| (740) 423-3634 | |
| (740) 423-3635 |
| Full Name | Dr Joseph A Shehadi |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 31 Years |
| Location | 807 Farson St Ste 136, Belpre, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174560890 | NPI | - | NPPES |
| 2335342 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35.081254 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Altru Hospital | Grand forks, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acute Care Surgery Of South Dakota Pc | 5698195030 | 43 |
News Archive
Integrated DNA Technologies (IDT) has pooled its expertise in genome editing into a free web resource dedicated to providing researchers a hub of information on the very latest in using the CRISPR/Cas9 system.
Researchers at the BBSRC-supported Babraham Institute have mapped the physical structure of the nuclear landscape in unprecedented detail to understand changes in genomic interactions occurring in cell senescence and ageing. Their findings have allowed them to reconcile the contradictory observations of two current models of ageing: cellular senescence of connective tissue cells called fibroblasts and cellular models of an accelerated ageing syndrome.
New research is speeding the development of brain-controlled devices that may soon allow amputees and paraplegics to use their limbs.
The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.
Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease, a condition for which there is currently no approved treatment.
› Verified 3 days ago
| Entity Name | Acute Care Surgery Of South Dakota Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730797184 PECOS PAC ID: 5698195030 Enrollment ID: O20230411001580 |
News Archive
Integrated DNA Technologies (IDT) has pooled its expertise in genome editing into a free web resource dedicated to providing researchers a hub of information on the very latest in using the CRISPR/Cas9 system.
Researchers at the BBSRC-supported Babraham Institute have mapped the physical structure of the nuclear landscape in unprecedented detail to understand changes in genomic interactions occurring in cell senescence and ageing. Their findings have allowed them to reconcile the contradictory observations of two current models of ageing: cellular senescence of connective tissue cells called fibroblasts and cellular models of an accelerated ageing syndrome.
New research is speeding the development of brain-controlled devices that may soon allow amputees and paraplegics to use their limbs.
The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.
Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease, a condition for which there is currently no approved treatment.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph A Shehadi, MD 416 Colegate Dr Bldg 3, Marietta, OH 45750-9549 Ph: (740) 568-4814 | Dr Joseph A Shehadi, MD 807 Farson St Ste 136, Belpre, OH 45714-1068 Ph: (740) 423-3634 |
News Archive
Integrated DNA Technologies (IDT) has pooled its expertise in genome editing into a free web resource dedicated to providing researchers a hub of information on the very latest in using the CRISPR/Cas9 system.
Researchers at the BBSRC-supported Babraham Institute have mapped the physical structure of the nuclear landscape in unprecedented detail to understand changes in genomic interactions occurring in cell senescence and ageing. Their findings have allowed them to reconcile the contradictory observations of two current models of ageing: cellular senescence of connective tissue cells called fibroblasts and cellular models of an accelerated ageing syndrome.
New research is speeding the development of brain-controlled devices that may soon allow amputees and paraplegics to use their limbs.
The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.
Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease, a condition for which there is currently no approved treatment.
› Verified 3 days ago
Seyed Abdolreza Ghodsi, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 807 Farson St Ste 136, Belpre, OH 45714 Phone: 740-423-3634 Fax: 740-423-3635 | |
Houman H Khosrovi, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 407 Main St Ste 2, Belpre, OH 45714 Phone: 304-865-3600 |